J
Judith Hsia
Researcher at AstraZeneca
Publications - 163
Citations - 26695
Judith Hsia is an academic researcher from AstraZeneca. The author has contributed to research in topics: Women's Health Initiative & Estrogen. The author has an hindex of 58, co-authored 138 publications receiving 25272 citations. Previous affiliations of Judith Hsia include George Washington University & University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial
Howard D. Sesso,Pamela M. Rist,Aaron K. Aragaki,Susanne Rautiainen,Lisa G. Johnson,Georgina Friedenberg,Trisha Copeland,Allison Clar,Samia Mora,M.V. Moorthy,A. Sarkissian,Jean Wactawski-Wende,William R Carrick,Garnet L. Anderson,JoAnn E. Manson,Susanne Rautiainen Lagerstrom,Shari S. Bassuk,Lu Wang,Aditi Hazra,Heike Gibson,Meryl S. LeBoff,Olivia I. Okereke,Deirdre K Tobias,Nancy R. Cook,Paulette D. Chandler,William G. Christen,Jasmah Hanna,Denise M. D'Agostino,M. Vinayagamoorthy,Eunjung Kim,Martin Van Denburgh,Gregory Kotler,Chunying Li,Vadim Bubes,Douglas C Smith,Eduardo Castro Pereira,Melvyn Okeke,Elise C. Roche,David Bates,C. Ridge,Alexandra Phillips,Brielle Salvo,Anna S Wilson,Leah R. Hall,Jimaldy Baez,Young-Hwan Sim,Hayara Cardoso,Gabriel Senor,Connor Rudnicki,Hanh Huynh,Viviane T. Nguyen,Nicholas James Terrell,Beth A Holman,Joseph Walter,L. Johnson,Amy Casarella,Julia Grella O’Connell,Luc Djoussé,Deidre K Tobias,Zareen Farukhi,Xuehong Zhang,Kenneth Breen,George V Menjin Jr,Rolando Rodriguez,Shamikhah Curry,Leah Arsenault,Olubunmi A Solano,Alison Weinberg,Jennifer Coates,Matthew Kilroe,Lincoln Zernicke,Katelyn Hasson,Karen J Matthew,C. Pfeffer,Julie Duszlak,Vincent Guzman,J. Falcón,Alexandro Badea Romero,Henry Kupets,F.C. Cortez,James C LeSuer,Andrea Hrbek,Eileen Bowes,P Quinn,Megan Mele,Lesley F. Tinker,Megan Skinner Herndon,Sue L. Mann,Mary Pettinger,Rebecca P. Hunt,Bill Carrick,Kate Szyperski,Lori Proulx-Burns,Elizabeth Burrows,Marian C. Limacher,Judith Hsia,Ganesh Asaithambi,Muhib Khan,Nandakumar Nagaraja,Lenore Ocava,Jana Wold,Brian H. Silver,Stephanie Connelly,Gretchen Van Lom,Cris Garvida,Kathy Hightower,Patrick Spaulding,Weili Lin,Janet B. Schoenberg,Patti Olee,Lawrence Sanford Cohen,Theodore Colton,I. C. Henderson,Stephen B. Hulley,Alice H. Lichtenstein,Eugene R. Passamani,Rebecca A. Silliman,Nanette K. Wenger,Shari E. Ludlam,Hagen Schroeter,Michel Faré,Javier Ottawani,Catherine Kwik-Uribe,Cassandra Arnaiz,Annabelle M. Costanza,John Greene,P. Hennessey,Sarma Vadlamani,Mallik Karmsetty,Paul Martini,Jan-Willem van Klinken,Alpa V Shah,Lori Stern +132 more
TL;DR: A daily MVM supplement did not significantly reduce the incidence of total cancer among older men and women and future studies are needed to determine the effects of MVMs on other aging-related outcomes among older adults.
Journal ArticleDOI
Evaluation of the Pharmacokinetic Interaction Between Ticagrelor and Venlafaxine, a Cytochrome P-450 2D6 Substrate, in Healthy Subjects
TL;DR: Ticagrelor is not expected to affect CYP2D6-mediated drug metabolism to a clinically relevant extent and was well tolerated whether given alone or in combination.
Journal ArticleDOI
Crushing ticagrelor tablets accelerates exposure compared with intact tablets
TL;DR: Ticagrelor reduced MI and CV death in patients with acute coronary syndromes in the PLATelet inhibition and patient Outcomes (PLATO) study.
Journal ArticleDOI
Sex‐Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD
Connie N. Hess,Iris Baumgartner,Sonia S. Anand,Mark R. Nehler,Manesh R. Patel,Eike Sebastian Debus,Michael Szarek,Warren H. Capell,Eva Muehlhofer,Scott D. Berkowitz,Lloyd Haskell,Rupert Bauersachs,Marc P. Bonaca,Judith Hsia +13 more
TL;DR: Women and men were at similar risk for the primary outcome, but a trend for greater risk of unplanned index limb revascularization among women was observed, and Effects of rivaroxaban were consistent by sex, though women more often discontinued treatment.
Journal ArticleDOI
Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization
Connie N. Hess,Michael Szarek,Sonia S. Anand,Rupert Bauersachs,Manesh R. Patel,Eike Sebastian Debus,Mark R. Nehler,Warren H. Capell,Joshua A. Beckman,Gregory Piazza,Stanislav Henkin,Alessandra Bura-Rivière,Holger Lawall,Karel Roztocil,Judith Hsia,Eva Muehlhofer,Scott D. Berkowitz,Lloyd Haskell,Marc P. Bonaca +18 more
TL;DR: Patients who underwent LER for PAD were at risk for VTE in addition to arterial thrombotic events, and low-dose rivaroxaban plus aspirin should be considered for reduction of the full spectrum of thromBotic risk.